New therapies for the treatment of advanced non-small cell lung cancer: Inhibitors of the epidermal growth factor receptor and angiogenesis;Nieuwe middelen voor de behandeling van gemetastaseerd niet-kleincellig longcarcinoom: Remmers van de epidermale groeifactorreceptor en van de angiogenese

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 16, 2008, Pages 928-932

  Lind, J S W ^a   Herder, G J M ^a   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; LAPATINIB; MATUZUMAB; PACLITAXEL; PANITUMUMAB; PLACEBO; SORAFENIB; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB; ZALUTUMUMAB;

ADENOCARCINOMA; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DRUG INHIBITION; DRUG TARGETING; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; RACE DIFFERENCE; REVIEW; SMOKING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 44949164530     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Groen HJM, Smit EF, Sleijfer DTh. Chemotherapie bij gemetastaseerd niet-kleincellig longcarcinoom. Ned Tijdschr Geneeskd. 2004;148:1670-4.
2. Bencardino K, Manzoni M, Delfanti S, Riccardi A, Danova M, Corazza GR. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Intern Emerg Med. 2007;2:3-12.
3. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 2004;22:777-84.
4. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 2004;22:785-94.
5. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, de Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol. 2007;25:1545-52.
6. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-9.
7. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet. 2005;366:1527-37.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32.
9. Radema SA, Witteveen PO, Gebbink MBFG, Voest EE. Het klinisch perspectief van angiogeneseremmers. Ned Tijdschr Geneeskd. 2003;147:1675-80.
10. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50.
11. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsch V, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract]. J Clin Oncol. 2007;25(Suppl):18S.
12. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-91.
13. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol. 2007;25:4743-50.